Prostatype Genomics
Prostate cancer is one of the most common forms of cancer and approximately 1.3 million men are diagnosed annually. Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test Prostatype®. Prostatype® is a genetic test that provides a comprehensive assessment of the aggressiveness of prostate cancer.
The Prostatype prognostic gene test helps doctors and patients make correct treatment decisions for individuals with prostate cancer. By minimizing over- and under-treatment, the quality of life for patients can be improved and resources can be saved within healthcare.
Using prostate tissue from the biopsy obtained at the time of diagnosis (i.e. no new sampling of the prostate is needed), the Prostatype® test system combines gene expression information from three stem genes with currently used clinical parameters (PSA, Gleason Score, and Tumor Stage) and calculates the so-called P-score, which shows the risk of dying from prostate cancer.
Rights issue 2026
On 29 June 2026, Prostatype Genomics AB (“Prostatype Genomics” or the “Company”) announced that the Board of Directors had resolved to carry out an issue of units – shares and two series of warrants – of initially up to approximately SEK 47.4 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The rights issue is covered by pre-subscription and underwriting commitments totalling approximately SEK 33.1 million, corresponding to approximately 70 percent of the Rights Issue. The purpose of the Rights Issue is to finance the continued Medicare reimbursement approval process and commercialization activities in the United States and Europe.